An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate.
Phase of Trial: Phase I
Latest Information Update: 31 May 2016
At a glance
- Drugs Tabalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 01 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2013 Planned End Date changed from 1 Oct 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.